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Identity 
Other names: EWSR2; SIC-1 
HGNC (Hugo): FLI1 
Location: 11q24.3 
Note 
NCBI mRNA Reference Sequence: 
- NM_008026.4 (mus musculus) 
- NM_002017.3 isoform 1 (homo sapiens) 
- NM_001167681.1 isoform 2 (homo sapiens) 
DNA/RNA 
Description 
Both the mouse and human fli-1 genes are 
approximately 120 kb, consist of 9 exons, and encode 
two protein isoforms, p51 (452 aa) and p48 (419 aa) 
(Sarrazin et al., 2000). Fli-1 is located on mouse 
chromosome 9 and human chromosome 11q24.1, a 
region of several abnormalities in human disease (Ben-
David et al., 1990; Truong and Ben David, 2000). The 
fli-1 gene is located within 240 kb of the ets-1 locus, 
suggesting that these Ets transcription factors aroe by 
gene duplication from a common ancestral gene (Ben-
David et al., 1991). The first fli-1 intron is the largest at 
approximately 64 kb in length, and the last exon, 9, 
containing the Ets DNA binding domain, is the largest 
at approximately 2808 bp in length (Figure 1). The 
sequence of the 5'-untranslated region (UTR) is located 
within exon 1, while the sequence of the 3'-UTR is 
located within exon 9. At least two ATG translation 
initiation sites have been localized to nucleotide 342 
(exon 1) and 441 (exon 2) of the human Fli-1 mRNA 
sequence (NM_002017.3),  
responsible for the generation of the two protein 
isoforms, p51 and p48 (Sarrazin et al., 2000). The 
second isoform, p48, has a shorter N-terminus, contains 
a distinct 5'UTR, and lacks an in-frame portion of the 5' 
coding region, compared to isoform 1, p51. The 
sequences flanking the transcription initiation (CAP) 
sites show 94% conservation between the human and 
mouse isoforms. The fli-1 promoter contains a potential 
TATA box element, and multiple regulatory elements. 
These include GATA, EBS, GT-rich, GC-rich, AP-2, 
AP-3 and CTC elements, some of which are conserved 
between mouse and human. The fli-1 promoter also 
contains binding sites for Sp-1, c-Myc, GATA-1, Ets-2, 
Oct-3, TBP, PEA-3, EBP, ATF/CREB, and E2A-PBX1 
(Barbeau et al., 1996; Barbeau et al., 1999; Dhulipala et 
al., 1998). The highly conserved 5' non-translated 
region of exon 1 is predicted to form a very stable 
hairpin structure, capable of post-transcriptional 
autoregulation (Barbeau et al., 1996). 
Transcription 
Transcription of the mouse fli-1 gene produces a full-
length mRNA transcript of 3087 bp, and a processed 
length of 1359 bp. Transcription of the human fli-1 
gene produces a full-length mRNA transcript of 3993 
and 3941 bp, and a processed length of 1359 and 1260 
bp, respectively. 
Pseudogene 
Although a pseudogene has not been identified for the 
fli-1 gene, comparison of the amino acid sequences of 
Fli-1 has revealed an 80% homology to the Ets-related 
protein Erg, localized adjacent to the ets-2 gene, on 
mouse chromosome 16 (Watson et al., 1992) and 
human chromosome 21q22. 
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Figure 1: Genomic organization of human fli-1. The fli-1 gene is localized on human chromosome 11q23, contains nine exons 
extending over approximately 120 kb, with a processed mRNA transcript length of 1359 bp, and encodes two protein isoforms of 452 aa 




The fli-1 gene encodes two isoforms of 51 and 48 kDa, 
synthesized by alternative translation initiation sites, as 
mentioned above. Loss of function studies have 
provided evidence to suggest that both the p51 and p48 
isoforms retain the same functional domains and 
activity (Melet et al., 1996). The functional domains 
located within the Fli-1 protein include the 5' Ets 
domain, and a Fli-1-specific region (FLS) referred to as 
the amino terminal transcriptional activation (ATA) 
domain, and a 3' Ets and carboxy terminal 
transcriptional activation (CTA) domain (Figure 2). 
The 5' Ets domain, sharing 82% sequence identity to 
Erg and 59-60% to Ets-1 and Ets-2, is located within 
amino acids 121-196. The FLS, which is absent in the 
Erg protein, is localized within amino acids 205-292. 
The 3' Ets domain, sharing 98% homology with Erg, is 
located within amino acids 277-360 and is responsible 
for sequence specific DNA-binding activity. The CTA 
domain, located within amino acids 402-452, is also 
involved in transcriptional activation and protein-
protein interaction. Both the 5' and 3' Ets domain 
contain sequences of helix 1-loop-helix 2 (H-L-H) 
secondary structures that are also present in Erg (Rao et 
al., 1993), while the FLS and CTA domains contain 
sequences which resemble turn-loop-turn (T-L-T) 
secondary structures. The structures of the ATA and
CTA domains contribute to the transcriptional activity 
of Fli-1. It has been suggested that the CTA region may 
serve simultaneously as a transcriptional activator nd 
repressor (Rao et al., 1993). Recently, mice engineered 
to lack the CTA domain of Fli-1 by homologous 
recombination were shown to express negligible to low 
levels of the mutant of Fli-1 mRNA and protein 
(Spyropoulos et al., 2000). Furthermore, the 
recombinant Fli-1 protein lacking the CTA domain 
displayed only 50-60% of the transcriptional activity of 
wild- type Fli-1, providing further evidence of the CTA 
domain's involvement in transcriptional activation. The 
reduced levels of mutant Fli-1 in these mice suggest 
that the CTA domain also functions to autoregulate Fli-
1 expression. NMR spectroscopy analyses have shown 
that the 3' Ets domain of Fli-1 consists of three alph -
helices and a four stranded beta-sheet that resembles 
the structures of the class of helix-turn-helix DNA-
binding proteins found in the catabolite activator 
protein of Escherichia coli, as well as those of several 
eukaryotic DNA binding proteins including H5, HNF-
3/forkhead, and the heat shock transcription factor 
(Liang et al., 1994a; Liang et al., 1994b). A comparison 
of the Fli-1 3' Ets domain to other structures has 
suggested that this 3' Ets domain uses a new variation 
of the winged helix-turn-helix motif for binding to 
DNA (Liang et al., 1994b). 
Fli-1 binds to DNA in a sequence-specific manner, and
it has been determined that the optimal DNA binding 
sequence for Fli-1 is ACCGGAAG/aT/c (Solomon and 
Kaldis, 1998; Mao et al., 1994; Cui et al., 2009). The 
bases flanking the core GGA Ets DNA-binding motif 
synergistically contribute to binding specificity among 
different Ets transcription factors. Gene promoters 
containing these Ets sequences have been shown to be 
transcriptionally regulated by Fli-1, including bcl-2 
(Lesault et al., 2002), MDM2 (Truong et al., 2005), 
gpIX, gpIIb (Bastian et al., 1999), mpl (Deveaux et al., 
1996), and recently SHIP-1 (Lakhanpal et al., 2010). 
Phosphorylation of both Fli-1 protein isoforms has 
been predominately detected on serine residues. This 
phosphorylation is modulated by the concentration of 
intracellular calcium, similar to Ets-1 and Ets-2, and 
dephosphorylation is controlled, at least in part, by the 
phosphatase PP2A (Zhang and Watson, 2005). Post-
translational modification by phosphorylation effects 
Fli-1 DNA binding, protein-protein interaction and 
transcriptional activation, thereby contributing to the 
control of gene function (Zhang and Watson, 2005; 
Asano and Trojanowska, 2009). 
Expression 
Fli-1 is highly expressed in all hematopoietic tissue  
and endothelial cells, and at a lower level in the lungs, 
heart and ovaries (Ben-David et al., 1991; Melet et al., 
1996; Hewett et al., 2001; Pusztaszeri et al., 2006). The 
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ubiquitous expression of Fli-1 in all endothelial cells 
(Hewett et al., 2001) suggests a role for Fli-1 in 
endothelial cell fate and angiogenesis. It has been 
suggested that Fli-1 is the first dependable nuclear 
marker of endothelial differentiation (Rossi et al., 
2004), is essential for embryonic vascular development 
(Spyropoulos et al., 2000), and acts as a master 
regulator establishing the blood and endothelial 
programmes in the early embryo (Gaikwad et al., 2007; 
Liu et al., 2008). Moreover immunohistochemical 
analysis has revealed that Fli-1 expression is a valuable 
tool in the diagnosis of benign and malignant vascular 
tumors. 
Localisation 
Similar to other Ets proteins, Fli-1 is a nuclear 
transcription factor and is generally localized within the 
nucleus, although Fli-1 protein has also been detect d 
in the cytoplasm of specific cell types (Cui et al., 2009; 
Pusztaszeri et al., 2006). 
Function 
Fli-1 plays an important role in erythropoiesis. The 
constitutive activation of fli-1 in erythroblasts leads to a 
dramatic shift in the Epo/Epo-R signal transduction 
pathway, blocking erythroid differentiation, activating 
the Ras pathway, and resulting in massive Epo-
independent proliferation of erythroblasts (Tamir et al., 
1999; Zochodne et al., 2000). These results suggest that 
Fli-1 overexpression in erythroblasts alters their 
responsiveness to Epo and triggers abnormal 
proliferation by switching the signaling event(s) 
associated with terminal differentiation to proliferation 
(Zochodne et al., 2000). The constitutive suppression of 
Fli-1, mediated through RNA interference or dominant 
negative protein expression has revealed an essential 
role for continuous Fli-1 overexpression in the 
maintenance and survival of the malignant phenotype 
in both murine and human erythroleukemia (Cui et al., 
2009). 
Homology 
Fli-1 is a member of the Ets transcription factor gene 
family. It is most related to Erg, located on mouse 
chromosome 16 and human chromosome 21. Similar to 
Fli-1, Erg is also activated through chromosomal 
translocation in human cancer. In prostate cancer, 
TMPRSS2 generates a fusion with ETV1, ETV4 and 
ETV5, and Erg share 98% homology within the Ets 
DNA binding domain. The fli-1 gene is conserved in 




Fli-1 aberrant regulation is often associated with 
malignant transformation. Fli-1 was first identified as a 
target of proviral integration in F-MuLV-induced 
erythroleukemia (Ben-David et al., 1990). In addition 
to Friend erythroleukemia, integration at the fli-1 locus 
also occurs in leukemias induced by the 10A1 (Ott et 
al., 1994), Graffi (Denicourt et al., 1999), and Cas-Br-E 
viruses (Bergeron et al., 1991). While Fli-1 activation 
is associated with viral integration in mice, it is also 
associated with chromosomal abnormalities in humans. 
In Ewing's sarcoma and primitive neuroectodermal 
tumors a chromosomal translocation results in a 
chimeric EWS/Fli-1 fusion protein, containing the 5' 
region of EWS and the 3' ETS region of Fli-1 (Delattre 
et al., 1992). This oncoprotein acts as an aberrant 
transcriptional activator with strong transforming 
capabilities. In addition, Fli-1 has been implicated in 
human leukemias, such as Acute Myelogenous 
Leukemia (AML), involving loss or fusion of the tel 
gene (Kwiatkowski et al., 1998). Binding of wildtype 
Tel, an ETS transcription factor, to Fli-1 inhibits Fli-1's 
regulatory function. Therefore loss of the tel gene or 
generation of the Tel-AML fusion protein by 
chromosomal translocation eliminates the normal 
regulation of Fli-1 leading to an increase in Fli-1 
activity. Tissue microarray and immunohistochemistry 
has also revealed the expression of Fli-1 in a wide 
variety of benign and malignant tumors, such as 
capillary hemangioma, neuroblastoma, small cell lung 
carcinoma, glioblastoma, medullar breast carcinoma, 
non-Hodgkin's lympoma, angiosarcoma, Kaposi's 
sarcoma and lymphoblastic lymphomas (Mhawech-
Fauceglia et al., 2006). 
 
Figure 2: Fli-1 functional domains. Both human and murine Fli-1 proteins consist of 452 amino acids (aa) which contain the following 
domains: ATA: amino-terminal transcriptional activation domain, FLS: Fli-1 specific domain, CTA: carboxy-terminal transcriptional 
activation domain, H-L-H: helix-loop-helix structure, and T-L-T: turn-loop-turn structure. 
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Implicated in 
Ewing's sarcoma and primitive 
neuroectodermal tumors 
Note 
Ewing's sarcoma is a malignant bone tumor affecting 
children. Such tumors usually develop during puberty, 
however there are few symptoms. Primitive 
neuroectodermal tumors are a rare group of tumors 
originating in cells from the primitive neural crest 
usually found in children under 10 years of age. 
Prognosis 
Since the EWS gene is fused to the fli-1 gene in the 
majority of Ewing's sarcomas, primers spaning these 
genes are used to amplify the junction for genetic 
diagnosis (Downing et al., 1995). 
Oncogenesis 
Expression of the EWS/Fli-1 fusion gene in the 
majority of Ewing's sarcomas is shown to be critical for 
cancer induction. Downregulation of this fusion 
oncoprotein using RNA interference inhibits cell 
growth and promotes apoptosis (Dohjima et al., 2003). 
Jacobsen or Paris-Trousseau syndrome 
Note 
A relatively infrequent congenital disorder in whic the 
fli-1 gene is commonly deleted. Clinical abnormalities 
include growth and mental retardation, cardiac defects, 
dysmorphogenesis of the digits and face, pancytopenia, 
and thrombocytopenia (Krishnamurti et al., 2001; 
Favier et al., 2003; Wenger et al., 2006). 
Prognosis 
Chromosomal deletions result in Fli-1 deficiency. 
Systemic lupus erythematosus (SLE) 
Note 
A chronic autoimmune disease with variable 
symptoms, commonly affecting the skin, joints, 
kidneys, heart and lungs. 
Prognosis 
SLE patients display Fli-1 overexpression in peripheral 
blood leukocytes (Mayor et al., 2000). Interestingly, 
Fli-1 overexpression also occurs in the MRL/lpr murine 
lupus model, and a 50% reduction of Fli-1 levels 
markedly prolongs survival and significantly reduces 
renal disease in these mice (Mayor et al., 2000). 
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